Preliminary results from a Phase 1 clinical trial suggest that everolimus (RAD001), in combination with Revlimid (lenalidomide), may have potential in the treatment of relapsed/refractory multiple myeloma. The findings were presented on June 4 at the American Society of Clinical Oncology (ASCO) annual meeting.

Everolimus is marketed by Novartis under the brand name Afinitor for the treatment of advanced kidney cancer and under the name Zortress to prevent kidney transplant rejection.  Everolimus is currently being investigated as a potential treatment for multiple…

Treatment of newly diagnosed multiple myeloma patients with a combination of cyclophosphamide (Cytoxan), Velcade (bortezomib), and dexamethasone (Decadron) (abbreviated CyBorD) appears to be effective and safe. The findings were presented June 5 in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

The study compared CyBorD with Revlimid (lenalidomide)-dexamethasone treatment (abbreviated RD) and cyclophosphamide-Revlimid-dexamethasone treatment (abbreviated CRD). The results of the Phase 2 trials indicate that RD and CyBorD treatment were similar in efficacy and safety. CRD, however, was not as effective…

Results of two Phase 1b clinical trials suggest that panobinostat in combination with Velcade (bortezomib) or Revlimid (lenalidomide) and dexamethasone (Decadron) is effective and well-tolerated in patients who are resistant (refractory) to previous multiple myeloma treatment. The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago in early June.

“There are novel therapies that have improved the outcome, literally doubled the survival, of patients with myeloma. Despite these incredible advances, inevitably most patients relapse, and so we…

In a recent study, treatment with Zometa (zoledronic acid) increased overall and progression-free survival rates among multiple myeloma patients compared to Bonefos (clodronate). Additionally, Zometa was more effective in preventing bone loss and fractures. The results were presented June 6 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago by Dr. Gareth Morgan of the Royal Marsden Hospital in London.

Bone is in a constant balance of being broken down and being replenished. A perfect balance keeps a person’s bones strong. However, in multiple myeloma…

Preliminary results from two ongoing clinical trials suggest that elotuzumab in combination with either Velcade (bortezomib) or Revlimid (lenalidomide) plus low-dose dexamethasone (Decadron) is effective and well-tolerated in patients who have relapsed or are resistant (refractory) to previous myeloma treatment. The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Elotuzumab is a new drug being developed by Facet Biotech and Bristol-Myers Squibb as a potential treatment for multiple myeloma. It selectively targets proteins that are on the…